A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma

Inclusion Criteria: 1. Patients ≥ 18 years of age. 2. Patient must be able to give own signed informed consent. 3. Patients that present with advanced or metastatic (stage III/IV) malignant melanoma of the skin. 4. Patients that are planned to receive either: * Adjuvant treatment * 1st line treatment for metastatic disease * 2nd line treatment for metastatic disease 5. Patients with prior adjuvant treatment are allowed. 6. Patients receiving planned standard treatment of one or more of the following: * Chemotherapy regimens containing DTIC, TMZ and/or cisplatin * Immunotherapy (for example ipilimumab and/or anti-PD-L1/PD-1 therapies) * BRAF and/or MEK inhibitors 7. Patients were FFPE and fresh frozen tissue is available (both mandatory). Exclusion Criteria: \-